Free Trial
→ This simple indicator removes the “technical” out of technical trading (From ProsperityPub) (Ad)

Eledon Pharmaceuticals Q1 2024 Earnings Report

Eledon Pharmaceuticals logo
$4.29 -0.05 (-1.15%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Announcement Details

Quarter
Q1 2024
Date
5/9/2024
Time
N/A

Conference Call Resources

Powered by Quartr

Eledon Pharmaceuticals Earnings Headlines

Eledon Pharmaceuticals' Investigational Therapy Tegoprubart Successfully Used in Landmark Kidney Xenotransplant at Mass General Transplant Center
February 9, 2025 | nasdaq.com
Eledon's tegoprubart used in second pig-to-human kidney transplant
February 7, 2025 | msn.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 22, 2025 | WealthPress (Ad)
Eledon announces tegoprubart use in transplant of pig kidney into human
February 7, 2025 | markets.businessinsider.com
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
February 7, 2025 | globenewswire.com
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025 | globenewswire.com
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

View Eledon Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles